Journal
JOURNAL OF IMMUNOLOGY
Volume 169, Issue 4, Pages 2172-2179Publisher
AMER ASSOC IMMUNOLOGISTS
DOI: 10.4049/jimmunol.169.4.2172
Keywords
-
Categories
Funding
- NCI NIH HHS [CA15083, R01CA82677, R01CA80782] Funding Source: Medline
- NCRR NIH HHS [M01-RR00585] Funding Source: Medline
Ask authors/readers for more resources
Posttransplant lymphoproliferative disorder (PTLD) and B cell lymphomas induced by EBV continue to be a major life-threatening complication in transplant patients. The establishment and enhancement of T cell immunity to EBV before transplantation and immunosuppressive therapy could help diminish these complications, but the lack of an effective vaccine has limited this prophylactic approach. We describe here the identification of a peptide epitope from the EBV EBNA2 Ag that is capable of inducing in vitro CD4(+) T cell responses that inhibit the EBV-mediated B lymphocyte proliferation associated with PTLD. Most significantly, T cell responses to the EBNA2 epitope were found to be restricted by numerous MHC class II alleles (DR1, DR7, DR16, DR52, DQ2, and DQ7), indicating that this peptide is highly promiscuous and would be recognized by a large proportion (>50%) of the general population. These results are relevant for the design of a simple, inexpensive and widely applicable peptide-based vaccine to prevent PTLD in solid organ transplant patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available